{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:33:45Z","timestamp":1781811225411,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>We seek a simple and reliable tool to predict malignant behavior of pheochromocytoma and paraganglioma (PPGL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single-center prospective cohort study assessed size of primary PPGLs on preoperative cross-sectional imaging and prospectively scored specimens using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS). Multiplication of PASS points with maximum lesion diameter (in mm) yielded the SIZEPASS criterion. Local recurrence, metastasis or death from disease were surrogates defining malignancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>76 consecutive PPGL patients, whereof 58 with pheochromocytoma and 51 female, were diagnosed at a mean age of 52.0 \u00b1 15.2 years. 11 lesions (14.5%) exhibited malignant features at a median follow-up (FU) of 49 months (range 4-172 mo). Median FU of the remaining cohort was 139 months (range 120-226 mo). SIZEPASS classified malignancy with an area under the curve (AUC) of 0.97 (95%CI 0.93-1.01; p&amp;lt;0.0001). Across PPGL, SIZEPASS &amp;gt;1000 outperformed all known predictors of malignancy, with sensitivity 91%, specificity 94%, and accuracy 93%, and an odds ratio of 72 fold (95%CI 9-571; P&amp;lt;0.001). It retained an accuracy &amp;gt;90% in cohorts defined by location (adrenal, extra-adrenal) or mutation status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The SIZEPASS&amp;gt;1000 criterion is a lesion-based, clinically available, simple and effective tool to predict malignant behavior of PPGLs independently of age, sex, location or mutation status.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1235243","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T11:45:38Z","timestamp":1691149538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma\u2013 SIZEPASS"],"prefix":"10.3389","volume":"14","author":[{"given":"Helena","family":"Hanschell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Diaz-Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Blanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Talat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Galat\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Aylwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Martin","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/mp.2012.18","article-title":"Common features between chromaffin and neural progenitor cells","volume":"17","author":"Androutsellis-Theotokis","year":"2012","journal-title":"Mol Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3727\/096368912X638874","article-title":"Differentiation of chromaffin progenitor cells to dopaminergic neurons","volume":"21","author":"Vukicevic","year":"2012","journal-title":"Cell Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0022","article-title":"Isolation, characterization, and differentiation of progenitor cells from human adult adrenal medulla","volume":"1","author":"Santana","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/ijms24021418","article-title":"The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors-an overview of the latest classifications","volume":"24","author":"Gheorghi\u0219an-G\u0103l\u0103\u021beanu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00079","article-title":"Cancer stem cells in pheochromocytoma and paraganglioma","volume":"11","author":"Scriba","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/cen.12324","article-title":"Phaeochromocytoma [corrected] crisis","volume":"80","author":"Whitelaw","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/biomedicines10081813","article-title":"Clinical and pathological tools for predicting recurrence and\/or metastasis in patients with pheochromocytoma and paraganglioma","volume":"10","author":"Bima","year":"2022","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surg (United States)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0261","article-title":"15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma","volume":"22","author":"Tischler","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.41","article-title":"Neuroendocrine cancer. Closing the GAPP on predicting metastases","volume":"10","author":"Eisenhofer","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0339-y","article-title":"Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy","volume":"43","author":"Parasiliti-Caprino","year":"2020","journal-title":"Hypertens Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/biomedicines10061310","article-title":"From SGAP-model to SGAP-score: A simplified predictive tool for post-surgical recurrence of pheochromocytoma","volume":"10","author":"Parasiliti-Caprino","year":"2022","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-21-0370","article-title":"Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery","volume":"186","author":"Parasiliti-Caprino","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2265.1984.tb00074.x","article-title":"Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization","volume":"20","author":"Shapiro","year":"1984","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2013"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-011-0850-3","article-title":"Malignant pheochromocytoma: new malignancy criteria","volume":"397","author":"De Wailly","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.02.019","article-title":"Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas","volume":"68","author":"Gao","year":"2006","journal-title":"Urology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12495","article-title":"Metastatic pheochromocytoma and paraganglioma","volume":"45","author":"Angelousi","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score","volume":"33","author":"Wu","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas-A meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-010-9422-5","article-title":"Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center","volume":"39","author":"Szalat","year":"2011","journal-title":"Endocrine"},{"key":"B30","article-title":"Prognostic value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score) tests to separate benign from malignant neoplasms","volume":"91","author":"Mlika","year":"2013","journal-title":"Tunis Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"Ec01","DOI":"10.7860\/JCDR\/2016\/20565.8419","article-title":"Risk stratification in paragangliomas with PASS (Pheochromocytoma of the adrenal gland scaled score) and immunohistochemical markers","volume":"10","author":"Kulkarni","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001190","article-title":"Molecular profiling of pheochromocytoma and abdominal paraganglioma stratified by the PASS algorithm reveals chromogranin B as associated with histologic prediction of malignant behavior","volume":"43","author":"Stenman","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2008.02.007","article-title":"Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle\/apoptosis gene expression analysis","volume":"143","author":"Strong","year":"2008","journal-title":"Surgery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-010-0744-5","article-title":"Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy","volume":"34","author":"Agarwal","year":"2010","journal-title":"World J Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cancers11081070","article-title":"Pheochromocytomas and paragangliomas: new developments with regard to classification, genetics, and cell of origin","volume":"11","author":"Koopman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.11.016","article-title":"Reply to letter to editor regarding: \u201cA clinical prediction model to estimate the metastatic potential of Pheochromocytoma\/paraganglioma: ASES score\u201d","volume":"165","author":"Cho","year":"2019","journal-title":"Surg (United States)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.10.004","article-title":"Regarding: A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"165","author":"Mattoo","year":"2019","journal-title":"Surg (United States)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.908","article-title":"Diagnosis for pheochromocytoma and paraganglioma: A joint position statement of the Korean pheochromocytoma and paraganglioma task force","volume":"36","author":"Ku","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(91)90237-9","article-title":"Familial medullary-thyroid carcinoma and multiple endocrine neoplasia type-2b map to the same region of chromosome-10 as multiple endocrine Neoplasia type-2a","volume":"9","author":"Lairmore","year":"1991","journal-title":"Genomics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat Genet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/cancers14020269","article-title":"Genetic alterations in mitochondrial DNA are complementary to nuclear DNA mutations in pheochromocytomas","volume":"14","author":"Tabebi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0217","article-title":"Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment","volume":"30","author":"Tabebi","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/JME-22-016","article-title":"Genetic bases of pheochromocytoma and paraganglioma","volume":"70","author":"Casc\u00f3n","year":"2023","journal-title":"J Mol Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13059-016-1016-y","article-title":"Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine","volume":"17","author":"Petrovski","year":"2016","journal-title":"Genome Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0312","article-title":"Genetic ancestry correlates with somatic differences in a real-world clinical cancer sequencing cohort","volume":"12","author":"Arora","year":"2022","journal-title":"Cancer Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10142-023-00979-4","article-title":"Health inequity in genomic personalized medicine in underrepresented populations: a look at the current evidence","volume":"23","author":"Tawfik","year":"2023","journal-title":"Funct Integr Genomics"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1235243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T11:45:43Z","timestamp":1691149543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1235243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":49,"alternative-id":["10.3389\/fendo.2023.1235243"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1235243","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"article-number":"1235243"}}